Ascentage Pharma (ADR) (AAPG)
Develops and commercializes hematology therapies in China and global clinical trials.
$15.51
vs last close−0.36 (−2.27%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 0.06% | 15.0K ADS | |
|---|---|---|---|
| 7 holders · as of Jun 30, 2026 | |||
| Other | 99.94% | 23.23M ADS | |
| remainder | |||
23.24M ADS as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
13F, as of Jun 30, 2026
7 holders · 15.0K shares · 3 new positions · 4 increased · 2 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 13.8K | 0.06% | −2.2K | Aug 14, 2026 |
| Morgan Stanley | 919 | 0.00% | +421 | Aug 13, 2026 |
| Wells Fargo & Company/MN | 200 | 0.00% | +200new | Aug 14, 2026 |
| Eversource Wealth Advisors, LLC | 24 | 0.00% | 0 | Jul 24, 2026 |
| UBS Group AG | 15 | 0.00% | −109 | Aug 13, 2026 |
| BlackRock, Inc. | 6 | 0.00% | +6new | Aug 7, 2026 |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | +1new | Aug 5, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.